306 related articles for article (PubMed ID: 31517711)
1. Prophylactic treatment in hemophilic patients with inhibitors.
Haya S
Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S14-S18. PubMed ID: 31517711
[TBL] [Abstract][Full Text] [Related]
2. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
[TBL] [Abstract][Full Text] [Related]
3. The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing.
Mancuso ME; Mahlangu JN; Pipe SW
Lancet; 2021 Feb; 397(10274):630-640. PubMed ID: 33460559
[TBL] [Abstract][Full Text] [Related]
4. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
5. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
Levy GG; Asikanius E; Kuebler P; Benchikh El Fegoun S; Esbjerg S; Seremetis S
J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
[TBL] [Abstract][Full Text] [Related]
6. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
7. Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia.
Tiede A
Hamostaseologie; 2017; 37(4):307-310. PubMed ID: 29582931
[No Abstract] [Full Text] [Related]
8. The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges.
Trinchero A; Sholzberg M; Matino D
Hamostaseologie; 2020 Aug; 40(3):311-321. PubMed ID: 32726826
[TBL] [Abstract][Full Text] [Related]
9. Emicizumab for the treatment of haemophilia A: a narrative review.
Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab for hemophilia A with factor VIII inhibitors.
Young G; Callaghan M; Dunn A; Kruse-Jarres R; Pipe S
Expert Rev Hematol; 2018 Nov; 11(11):835-846. PubMed ID: 30278802
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
12. Spinal epidural hematoma in a child with hemophilia A with high titer inhibitors and follow-up with prophylactic emicizumab: case report and literature review.
Villarreal-Martínez L; Sepúlveda-Orozco MDC; García-Viera DA; Robles-Sáenz DA; Bautista-Gómez AJ; Ortiz-Castillo M; González-Martínez G; Mares-Gil JE
Blood Coagul Fibrinolysis; 2021 Sep; 32(6):418-422. PubMed ID: 33859115
[TBL] [Abstract][Full Text] [Related]
13. FEIBA versus NovoSeven in hemophilia patients with inhibitors.
Franchini M; Coppola A; Tagliaferri A; Lippi G
Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071
[TBL] [Abstract][Full Text] [Related]
14. Pioneering therapeutic proteins in hemophilia care through innovative technologies.
Pabinger-Fasching I; Négrier C
Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062
[No Abstract] [Full Text] [Related]
15. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
[TBL] [Abstract][Full Text] [Related]
16. Key issues in inhibitor management in patients with haemophilia.
Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
[No Abstract] [Full Text] [Related]
17. Safety first: Tracking adverse events associated with new therapies for people with hemophilia.
Recht M
J Thromb Haemost; 2021 Jan; 19 Suppl 1():3-5. PubMed ID: 33331044
[No Abstract] [Full Text] [Related]
18. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B; Geldziler B; Bjerre J; Seremetis S
Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
[TBL] [Abstract][Full Text] [Related]
19. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors in haemophilia: clinical aspects.
Dimichele D; Rivard G; Hay C; Antunes S
Haemophilia; 2004 Oct; 10 Suppl 4():140-5. PubMed ID: 15479387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
